Tilray stock price forecast: $7.22 resistance in focus as TLRY rises 3.58%

Traders Union
All News
Financial News
Tilray gains 3.58% today to $5.65

Highlights

Tilray reported quarterly revenue of $206.73 million and a net loss of $0.24 per share, missing consensus estimates and heightening uncertainty.
Management reaffirmed full-year adjusted EBITDA guidance of $62–72 million and emphasized ongoing efforts to stabilize operations and reassure stakeholders.
Technicals show persistent bearish pressure, with TLRY expected to trade between $5.10 and $6.20; momentum indicators broadly favor further downside.

Earnings miss and guidance effort drive mixed investor sentiment

Tilray's latest earnings release revealed revenue of $206.73 million and a net loss of $0.24 per share for the fiscal quarter ending February 28, 2026, falling short of consensus expectations and creating renewed earnings uncertainty. The company reiterated its full-year adjusted EBITDA guidance between $62 million and $72 million, signaling continued efforts to stabilize operations and reassure stakeholders. Additionally, Tilray Medical announced participation in the Cannabis Europa London 2026 conference to engage in policy discussions on medical cannabis in Europe. These developments reflect a mixed fundamental backdrop, with near-term price action responding to both disappointing results and modestly positive forward statements.

Downward trend persists as mixed momentum signals limit upside

On the technical front, $5.65 is just above the MA-20 level of $5.64, but well below the MA-50 at $6.29 and MA-200 at $9.69, indicating downward pressure from medium- and long-term trends. Immediate resistance is marked by the Ichimoku Kijun at $7.22. Momentum signals are conflicted: the MACD (D1) shows a strong sell bias, while the ADX is neutral; RSI (D1) reads 40.96, suggesting ongoing weakness, but the Stoch RSI is at 100, signaling potential short-term overbought conditions. The CCI is neutral, and BBP indicates buying activity consistent with today's positive price move, even as some intraday oscillators diverge.

Consolidation likely as low breakout odds follow bearish momentum

Looking to the next five trading days, TLRY is expected to trade between $5.10 and $6.20, reflecting typical volatility. There is less than a 20% probability of a sustained breakout to the upside, given broader bearish signals from higher timeframe moving averages and momentum indicators. The baseline scenario is for the price to consolidate sideways within the established band; a bullish breakout above $6.20 could see a test of resistance near $7.22, while a close below $5.10 could lead to accelerated declines as sellers retain longer-term control.

Viktoras Karapetjanc, expert at Traders Union, sees Tilray’s latest earnings miss as a setback, but notes management’s steady guidance and proactive participation in key industry events. He believes the company’s effort to stabilize fundamentals is resonating with investors, even as the technical picture is challenged by longer-term weakness. The newsflow and sentiment are creating tactical opportunities for active traders. With potential for a range-bound move ahead, Karapetjanc stays constructive. "If TLRY holds above $5.10, I expect sideways consolidation with an upside bias as optimism builds around forward guidance and sector engagement."

Earlier, analysts noted that Tilray faced a tug-of-war between short-term buyer optimism and persistent longer-term bearish momentum as it navigated evolving regulatory conditions and operational expansion. The current analysis reinforces this mixed outlook, with weaker-than-expected earnings and conflicted technical signals suggesting investors should closely monitor the $6.20 resistance for any signs of a meaningful bullish reversal in the near term.

Source of Data: TLRY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.